Новости за 12.01.2022

Quest Diagnostics Inc. offered guidance for the fourth quarter and full year on Wednesday that exceeded Wall Street estimates, driven by demand for COVID-19 testing services. The company is now expecting per-share earnings of $3.12 and adjusted EPS of $3.33, ahead of the $3.07 FactSet consensus. Revenue is expected to come to about $2.74 billion, ahead of the $2.56 billion FactSet consensus. For the full year, Quest is expecting EPS of $15.55 and adjusted EPS of $14.24, ahead of the $13.86 FactSet consensus. Читать дальше...

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

Apogee Enterprises Inc. said Wednesday it will raise its quarterly dividend by 10%, to 22 cents a share from 20 cents. The new dividend will be payable Feb. 15 to shareholders of record on Jan. 31. Based on Tuesday's stock closing price of $47.34, the new annual dividend rate implies a dividend yield of 1.86%, compared with the implied yield for the S&P 500 of 1.31%. Separately, the enclosing commercial buildings and framing art company said it increased its current share repurchase program by 2 million shares... Читать дальше...

Shares of Immuron Ltd. rocketed 49.6% in active premarket trading Wednesday, after the Australia-based biopharmaceutical company said it received an award of AUD$6.2 million ($4.5 million) from the U.S. Department of Defense to evaluate Travelan for military use. Trading volume spiked to 1.3 million shares, compared with the full-day average of about 60,500. The award is aimed at testing the efficacy of a single larger dose regimen of Travelan for the treatment of moderate to severe diarrhea... Читать дальше...

The number of Americans who are currently in hospitals with COVID-19 continues to set daily records at more than 140,000 as the highly transmissible omicron variant races across the country, but scientists are seeing signs the wave may soon peak. The seven-day average climbed to 140,6419 on Tuesday, according to a New York Times tracker, up 84% from two weeks ago. The daily average case number rose to 761,122, up 185% from two weeks ago, while the daily average for COVID-19-related deaths is up 40% from two weeks ago to 1,736. Читать дальше...

U.S. stock futures advanced Wednesday ahead of data that could show inflation accelerating to new heights.

South Korea has granted approval to the COVID-1i9 vaccine developed by Novavax Inc. in adults aged 18 and older, the company said Wednesday. The vaccine, known as NVX-CoV2373, is the first protein-based COVID-19 vaccine to be approved for commercial use in South Korea and will be manufactured in the country by SK bioscience. The vaccine has also received conditional marketing authorization in the EU and emergency use listing from the World Health Organization. The company is planning to submit... Читать дальше...

Even with subsidies, the Build Back Better child care proposal would put child care out of reach of working-class families

You might love it for its radiant heating, all-wheel drive, sustainability, and speed.

To have credit ready when you need it, the time to start building a good and lengthy credit history is now.

By taking the right precautions now, you can sleep soundly when the stock market drops and stays there for a while, something that's bound to happen.

Philips sees 4Q sales short of expectations, partly due to supply-chain issues

‘He sent us spreadsheets as a courtesy — and he said that even this is not a requirement.’

Prosecutors say Fesum Ogbazion duped taxpayers with promises of advances on their refunds and then buried them in fees.

Dr. Anthony Fauci was heard on a hot mic insulting Kentucky Sen. Rand Paul after questioning

Bank of America plans to end its $35 'non-sufficient funds' fees next month, and will drop overdraft fees to $10 from $35. Wells Fargo is also ending some fees.

Portfolios with stocks, mutual funds and ETFs under the ESG banner have a language issue, too often over-promising on sustainable issues relative to screeners.